<DOC>
	<DOCNO>NCT00796770</DOCNO>
	<brief_summary>The purpose study determine whether administration dendritic cell vaccine safe effective treatment HIV-1 patient .</brief_summary>
	<brief_title>Vaccination HIV-1 Infected Patients With Dendritic Cells Addition Antiretroviral Treatment - ( DALIA Trial )</brief_title>
	<detailed_description>The purpose study determine whether administration dendritic cell vaccine safe effective treatment HIV-1 patient . This phase I , single-center , study HIV infect patient . The primary objective evaluate safety vaccination schedule ( apheresis procedure week 24 ) week 24 safety Analytical Treatment Interruption ( ATI ; week 24 week 48 ) week 48 HIV-1 infected patient receive antiretroviral therapy least 12 month HIV-1 RNA ≤50 copies/mL CD4+ T cell count &gt; 500/mm3 entry trial receive , addition anti-retroviral therapy 24 week , vaccination ex vivo generate interferon-alpha dendritic cell load HIV-1 lipopeptides activate lipopolysaccharide ( BIIR/ANRS-HIVax-001 , DC vaccine product ) .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . ≥ 18 year old 2. write informed consent 3 . HIV1 infection document licensed ELISA test kit confirm Western Blot anytime prior study entry 4. treatment combination antiviral drug ( HAART ) least 12 month , stable treatment least 3 month prior enrollment . HAART define antiretroviral regimen consist least three registered antiretroviral drug ( 3 Nucs low dose ritonavir use boost protease inhibitor count one three antiretroviral agent ) 5 . CD4+ T cell count &gt; 500 cells/mm3 least two consecutive measurement ( include screen value ) within previous 6 month prior enrollment ( occasional CD4 cell count range 450500 cells/mm3 permit ) 6. nadir CD4+ T cell count &gt; 300 cells/mm3 prior HAART 7. plasma HIVRNA ≤ 50 copies/mL least two consecutive measurement ( include screen value ) within previous 3 month prior enrollment ( occasional call 'blips ' 200 copies/mL permit ) 8. history CDC class C event ( Appendix 2 ) 9. vaccination last 3 month 10. blood cell chemistry : 1. neutrophil ≥ 1,000/mm3 2. platelet ≥ 100,000/mm3 3. hemoglobin ≥ 10 g/dl 4. creatinin ≤ 1.5 x N 5 . ASAT , ALAT , conjugate bilirubin ≤ 2.5 x N 11 . Adequate Kidney Function proteinuria ≤ 1 g/l ( ++ ) urinalysis 1 . Nadir CD4+ T cell count &lt; 300 cells/mm3 prior HAART 2. pregnant lactate woman 3. prior chemotherapy treatment 4. interferon alpha ( IFNα2b ) sargramostim ( GMCSF ) &lt; 12 week begin trial 5. interleukin2 ( IL2 ) &lt; 12 week begin trial , 6. corticosteroid immunosuppressive agent &lt; 12 week begin trial 7. active asthma and/or treatment asthma , 8. history malignancy ( except basal carcinoma skin ) include hematologic malignancy AIDS defining malignancy , lymphoproliferative disorder Kaposi 's sarcoma . Patients Kaposi 's sarcoma limit skin disappear HAART therapy , without require systemic therapy , 1 year prior study entry eligible participate 9. angina pectoris congestive heart failure , autoimmune disease , evolutive pulmonary disease , organ failure 10. active infection include viral hepatitis 11. history thrombocytopenia 12. chronic hepatitis B C 13. previous exposure HIV experimental vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>HIV</keyword>
	<keyword>Vaccine</keyword>
	<keyword>HAART</keyword>
	<keyword>HIV-1</keyword>
	<keyword>AIDS</keyword>
	<keyword>Dendritic Cells</keyword>
	<keyword>DALIA</keyword>
</DOC>